HCK inhibitors for the treatment of fibrosis and cancer
US12378235B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 1, 2020 |
| Grant date | Aug 5, 2025 |
| Priority date | — |
| Expiry date | Sep 27, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F5/025
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds which are thiazole and triazole derivatives are disclosed, including compounds of the following genus: The compounds are inhibitors of hematopoietic cell kinase (HCK) and exhibit anti-fibrotic and anti-proliferative effects. They are useful in the treatment of a variety of disorders, including a fibrosis or a fibrotic disease, such as renal fibrosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.